Clincosm LogoSign in Get a demo

Epigenetic Biomarkers for Alzheimer's Disease

Sponsor
Chinese University of Hong Kong (Other)
Overall Status
Recruiting
CT.gov ID
NCT04081285
Collaborator
Hong Kong University of Science and Technology (Other)
250
Enrollment
1
Location
52
Anticipated Duration (Months)
4.8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Alzheimer's disease (AD) is a neurodegenerative disorder with no know cure. The pathogenesis of late onset AD (LOAD) is complex and multifactorial in nature, with multiple susceptibility genes and environmental factors at interplay.

The objective of this study is to improve our understanding of the risk factors of LOAD by conducting an epigenome wide study within patients of LOAD contrasted against their cognitively normal siblings.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    250 participants
    Observational Model:
    Cohort
    Time Perspective:
    Cross-Sectional
    Official Title:
    Identification of Epigenetic Biomarkers for Alzheimer's Disease in Blood Using Epigenome-wide Analysis
    Actual Study Start Date :
    Sep 1, 2019
    Anticipated Primary Completion Date :
    Dec 31, 2023
    Anticipated Study Completion Date :
    Dec 31, 2023

    Outcome Measures

    Primary Outcome Measures

    1. DNA methylation [5 years]

    2. RNA-seq microbiome [5 years]

    3. Alzheimer's disease Assessment Scale-cognitive subscale (Adas-Cog) [5 years]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    50 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Sufficient Cantonese competency for cognitive test

    • Written informed consent given

    • Have at least one gender-matched cognitively normal sibling

    Exclusion Criteria:

    • Subjects who refuse blood taking procedure

    • Do not have a reliable family/caregiver informant (personal contact at least once a month)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 The Chinese University of Hong Kong Hong Kong Hong Kong

    Sponsors and Collaborators

    • Chinese University of Hong Kong
    • Hong Kong University of Science and Technology

    Investigators

    • Principal Investigator: Timothy Kwok, Chinese University of Hong Kong

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Timothy Kwok, Professor, Chinese University of Hong Kong
    ClinicalTrials.gov Identifier:
    NCT04081285
    Other Study ID Numbers:
    • 2018.441
    First Posted:
    Sep 9, 2019
    Last Update Posted:
    Jan 11, 2022
    Last Verified:
    Jan 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Alzheimer Disease

    Study Results

    No Results Posted as of Jan 11, 2022